

# **Gold nanoparticles to ameliorate obesity related glucose intolerance**

**Jane Phui Mun NG**

**Submitted in total fulfilment of the requirements of the degree  
of Doctor of Philosophy (PhD)**

**4<sup>th</sup> January 2016**

**School of Life Sciences  
Faculty of Science  
University of Technology Sydney**

## Abstract

Obesity is associated with a number of metabolic disorders such as insulin resistance, glucose intolerance, and dyslipidaemia. The main objective of this research work focused on potential therapeutic applications of “naked” gold nanoparticles (AuNPs) in the treatment of obesity-related metabolic diseases. In this thesis, 21 nm spherical citrate-coated, unmodified also known as “naked” AuNPs were studied and assessed using both *in vitro* cell and *in vivo* animal studies. We observed an increased rate of “naked” AuNPs cellular uptake non-selectively and non-specific accumulation in all cell types studied compared to surface modified AuNPs. Macrophages in adipose tissue played a crucial role contributing to the low-grade chronic inflammation present in obesity and pathogenesis of obesity-related metabolic disorders. Our *in vitro* studies also showed that AuNPs can act on the complex adipocyte-macrophage interaction altering the adipocytes lipid and fatty acid metabolic markers in a macrophage-dependent manner.

Based on this unique finding, we further investigated the long-term safety of AuNP treatment and their effect on adipose tissue macrophages using *in vivo* mice model with dietary obesity. In this study, 7 week old male C57Bl/6 mice were fed a high fat diet (HFD) and received daily intraperitoneal injection of AuNPs (0.785 µg or 7.85 µg/g/day) for 9 weeks. Our results showed that the AuNP-treated mice with dietary obesity showed significantly improved body morphometry measurement with significantly reduced blood lipid levels and prevented the development of glucose intolerance. We proposed that the alterations in the local pro-inflammatory cytokine environment due to modification of macrophage activity by AuNPs may be the key underlying mechanism for the weight loss observed in the HFD-fed mice. In addition, there was no indication of liver toxicity after 9 weeks of daily AuNPs exposure.

Following that, male C57Bl/6 mice (7 week old) feeding a 10 week HFD were used as an *in vivo* obese model with chronic obesity and metabolic disorder to study the effect of short-term AuNP treatment. At week 10, the obese mice were continued on a HFD and AuNP treatment (0.0785 µg, 0.785 µg, or 7.85 µg/g/day) administered daily via intraperitoneal injection for an additional 5 weeks. Our findings showed that the 5

weeks AuNP-treated obese mice had little to no impact on body morphometric measurements of mice with existing obesity. However, all obese mice treated with 5 weeks of AuNPs showed amelioration of glucose intolerance. Our results also showed altered the inflammatory cytokines, lipid, and glucose marker expression in the liver. Our findings suggest that obese mice treated with AuNPs could have a lower the risk of developing obesity-related complications such as glucose intolerance and liver steatosis.

This research work demonstrated the anti-obesity and anti-diabetic properties of AuNPs which has led to our proposal that AuNPs can serve as a novel therapeutic treatment strategy in the prevention of obesity and obesity-related metabolic disorders.

## **Certificate of Original Authorship**

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as part of the collaborative doctoral degree and/or fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

Signature of Student:

(Jane Phui Mun Ng)

Date:

This research is supported by the University of Technology Sydney (UTS) International Research Scholarship and Australian Technology Network and International Strategic Technology Alliance (ATN ISTA) Nano Network Scholarship through Institute of Nanoscale Technology.

## Acknowledgements

My sincere gratitude to the school,

This research work is a collaborative and interdisciplinary study under the expert supervision from some of the greatest intellects in the field biology, medicine, chemistry, and biomedical engineering. My ideas would still be an idea without your acceptance and support. Thank you.

To the greatest minds of the science world,

It has been such a great honour to have met and learned from you all. First and foremost, I would like to thank my principal supervisor, A/Prof. Stella M. Valenzuela and co-supervisors, Dr. Hui Chen, Prof. Bruce K. Milthorpe, and A/Prof. Andrew D. McDonagh. Thank you for your guidance and taking the time to mentor me. Without your help, I would be lost. No words will ever describe the enormous role the both of you had played in my life and to making this thesis happen. Thank you.

I would like to express my sincere appreciation to A/Prof. Michael B. Cortie and Dr. Michael Coutts for their expertise in gold nanoparticles synthesis and characterization; Dr. Yi Tan who supported me in the first animal work along with animal house manager, Ms. Fiona Reed, and Dr. David P Bishop who assisted with the ICP-MS analysis. Special thanks to Dr. Kristine McGrath, Dr. Cathy Gorrie, Dr. Michael Johnson, Dr. Richard Wuhrer, Ms. Katie McBean, Dr. Freddrick Luk, Mr. Yik Lung Chan, and my peers at UTS. Each of you played a crucial part supporting me in this research. Thank you. Special thanks to my best friend Ms. Kit Yee Ng for writing macros to support my data and image analyses. To my mentors, Ms. Christine Gan, Mr. John & Mrs. Kerrie Wiersma for their encouragement through this impossible journey. Thank you.

To my beloved family, Esther, Thomas, Paul and John. Thank you for your unconditional love and support. I would not be here without you. I love you.

To my many friends that I may had missed, thank you for your kind support. I want to thank Australia and its people, for the hospitality and generosity this great country has provided me. Last but not least, I want to thank our Lord Jesus Christ for being there every step of the way.

## Table of contents

ABSTRACT .....	I
CERTIFICATE OF ORIGINAL AUTHORSHIP .....	III
ACKNOWLEDGEMENTS .....	IV
TABLE OF CONTENTS .....	V
LIST OF FIGURES .....	XIV
LIST OF TABLES .....	XVIII
ABBREVIATIONS .....	XX
1. LITERATURE REVIEW.....	2
1.1 Nanomedicine .....	2
1.2 Gold nanoparticles (AuNPs) .....	3
1.2.1 Synthesis of AuNPs .....	3
1.2.2 Surface modification and ligand conjugation of AuNPs .....	4
1.2.3 Physical and optical properties of AuNPs.....	6
1.2.3.1 Surface plasmon resonance .....	6
1.2.3.2 Scattering.....	7
1.2.3.3 Photothermal .....	7
1.2.4 Cellular uptake and toxicity of AuNPs .....	10
1.2.5 Biological interactions of AuNPs <i>in vivo</i> .....	11
1.3 Obesity .....	14
1.3.1 Role of adipose tissue.....	17
1.3.1.1 Adipogenesis .....	17
1.3.1.2 Dysregulation of adipokines .....	18

1.3.2	Role of liver.....	20
1.3.2.1	Ectopic lipid deposition and insulin resistance .....	20
1.3.3	Adipose tissue macrophages (ATMs) .....	22
1.4	Current treatment for obesity .....	23
1.4.1.1	Pharmaceutical interventions .....	24
1.4.1.2	Surgical intervention .....	27
1.5	Rationale of study .....	27
1.5.1	Inhibition of ATMs reduces insulin resistance and fat mass .....	28
1.5.2	Aims of thesis.....	28
2.	GOLD NANOPARTICLE SYNTHESIS, SURFACE MODIFICATION AND CHARACTERIZATION FOR USE IN <i>IN VITRO</i> CELL AND <i>IN VIVO</i> ANIMAL STUDIES. ....	31
2.1	Introduction.....	31
2.2	Methods.....	32
2.2.1	Preparation of tetrachloroauric acid (HAuCl <sub>4</sub> ) stock solution .....	33
2.2.2	Preparation of spherical citrate-coated AuNPs .....	35
2.2.3	Direct conjugation of biomolecules onto AuNPs.....	37
2.2.4	Preparation of MPCs .....	38
2.2.5	Biomolecule-conjugation of MPCs.....	42
2.2.6	<i>In vitro</i> cell cultures .....	42
2.2.6.1	Bovine aortic endothelial cell (BAEC) .....	42
2.2.6.2	Human coronary artery endothelial cell (HCAEC).....	43
2.2.7	Characterization techniques .....	43
2.2.7.1	UV-VIS spectrophotometry .....	43

2.2.7.2	Dynamic light scattering (DLS) and zeta ( $\zeta$ ) potential .....	44
2.2.7.3	Inductively-coupled plasma mass spectroscopy (ICP-MS).....	44
2.2.7.4	High-resolution scanning electron microscopy (HR-SEM).....	45
2.2.7.5	Agarose gel electrophoresis .....	46
2.2.7.6	Critical flocculation concentrations .....	46
2.2.7.7	Cytotoxicity assay .....	46
2.2.7.8	Cellular imaging and microscopy .....	47
2.3	Results .....	49
2.3.1	Characterization of 21nm AuNPs .....	49
2.3.1.1	Size and morphology of unmodified AuNPs and MPCs .....	49
2.3.1.2	SPR band and peak of unmodified AuNPs and MPCs .....	51
2.3.1.3	Critical flocculation concentration of unmodified AuNPs and MPCs....	55
2.3.1.4	Surface potential and charge of unmodified AuNPs and MPCs .....	58
2.3.2	Cellular uptake and labelling of unmodified AuNPs and MPCs .....	62
2.3.3	Cellular toxicity of unmodified AuNPs and MPCs .....	66
2.4	Discussion .....	68
3.	<i>IN VITRO</i> STUDY OF THE EFFECT OF GOLD NANOPARTICLES ON MACROPHAGES AND ADIPOCYTES .....	72
3.1.	Introduction .....	72
3.2.	Methods.....	73
3.2.1.	Cell culture and AuNP treatment .....	73
3.2.1.1.	Materials.....	73
3.2.1.2.	Murine RAW 264.7 macrophage-like cell line .....	74



3.2.1.3. Human U937 monocyte cell line.....	76
3.2.1.4. Murine 3T3-L1 fibroblast cell line.....	76
3.2.1.5. Co-culturing of murine mature adipocytes and macrophage cells.....	80
3.2.2. MTT assay.....	80
3.2.3. Intracellular reactive oxygen species (ROS) measurement .....	81
3.2.4. Western blot analysis .....	82
3.2.4.1. Protein isolation .....	82
3.2.4.2. Protein gel electrophoresis .....	83
3.2.5. Gene expression analysis using RT-PCR.....	84
3.2.5.1. RNA isolation .....	84
3.2.5.2. cDNA synthesis.....	84
3.2.5.3. TaqMan® gene expression assay detection .....	85
3.2.6. Cell supernatant analysis of secreted cytokines .....	87
3.2.7. Biochemical assays .....	88
3.2.7.1. Non-esterified free fatty acids (NEFA) concentration.....	88
3.2.7.2. Cell Supernatant Triglyceride concentration .....	89
3.2.8. Oil-red O staining of adipocytes .....	90
3.2.9. Insulin-mediated glucose uptake.....	91
3.2.10. Statistical analysis .....	92
3.3. Results.....	93
3.3.1. Effect of AuNP treatment on RAW 264.7 macrophage-like cell line.....	93
3.3.1.1. ROS production by RAW 264.7 macrophages following treatment with AuNPs .....	94

3.3.1.2. Protein expression in RAW 264.7 macrophages following treatment with AuNPs .....	96
3.3.1.3. mRNA expression of inflammatory markers in RAW 264.7 macrophages following treatment with AuNPs .....	100
3.3.2. Effects of AuNP treatment on U937 monocytic cell-line .....	102
3.3.2.1. Cytokine profile response of PMA-differentiated U937 macrophage-like cells following treatment with AuNPs .....	102
3.3.2.2. Cytokine profile response of LPS stimulated PMA-differentiated U937 macrophage-like cells following treatment with AuNPs .....	103
3.3.3. Effect of AuNP treatment on mature 3T3-L1 adipocytes .....	111
3.3.3.1. Cell viability of adipocytes treated with AuNPs.....	112
3.3.3.2. ROS production by adipocytes following treatment with AuNPs .....	112
3.3.3.3. Lipid profiles of adipocytes following treatment with AuNPs .....	116
3.3.3.4. Insulin-mediated glucose uptake in adipocytes following treatment with AuNPs .....	121
3.3.3.5. mRNA expression of adipokine markers in adipocytes following treatment with AuNPs .....	121
3.3.4. Effect of AuNP treatment on co-cultured adipocytes and macrophages .....	124
3.3.4.1. Cell viability of adipocyte-macrophage co-cultures following treatment with AuNPs .....	124
3.3.4.2. ROS production in co-cultured adipocytes-macrophages following their treatment with AuNPs .....	124
3.3.4.3. mRNA expression of inflammatory and adipokine markers in co-cultured adipocyte-macrophages following AuNP treatment .....	126
3.4. Discussion .....	130

4. TREATMENT OF HFD-INDUCED OBESITY IN MICE USING GOLD NANOPARTICLES .....	137
4.1. Introduction .....	137
4.2. Methods .....	140
4.2.2. Animal experiment .....	140
4.2.2.1. Tissue and blood sample collections .....	142
4.2.3. Glucose tolerance test .....	142
4.2.4. Biochemical assays .....	142
4.2.4.1. Determination of plasma NEFA concentration .....	143
4.2.4.2. Determination of plasma and liver tissue triglyceride concentrations ..	143
4.2.4.3. Determination of plasma insulin concentration .....	143
4.2.4.4. Determination of plasma cholesterol concentration .....	144
4.2.4.5. Determination of plasma alanine aminotransferase (ALT) concentration ..	146
4.2.4.6. Determination of plasma aspartate aminotransaminase (AST) concentration .....	146
4.2.5. Histological analysis .....	147
4.2.5.1. Tissue specimen preparation .....	147
4.2.5.2. Harris haematoxylin and eosin (H&E) tissue staining .....	147
4.2.6. Gene expression analysis using RT-PCR .....	148
4.2.6.1. RNA isolation and cDNA synthesis .....	148
4.2.6.2. Taqman® and SYBR ® Green gene expression assay .....	148
4.2.7. Tissue preparation and digestion for ICP-MS analysis .....	151
4.2.8. Statistical analysis .....	152



5.2.5. Histological analysis .....	187
5.2.5.1. H&E staining.....	187
5.2.5.2. Immunohistochemistry staining .....	188
5.2.6. Gene expression analysis using RT-PCR.....	189
5.2.6.1. RNA extraction and cDNA synthesis .....	189
5.2.6.2. Gene expression assays .....	189
5.2.7. Tissue preparation and digestion for ICP-MS analysis.....	189
5.2.8. Statistical analysis .....	190
5.3. Results.....	190
5.3.1. Effects of HFD consumption .....	190
5.3.1.1. Body measurements of obese mice .....	190
4.4.1.1. mRNA expression of inflammatory and adipokine markers in the adipose tissue .....	198
5.3.1.2. mRNA expression of inflammatory, lipid, and glucose markers in the liver .....	203
5.3.2. Effects of AuNP treatment.....	208
5.3.2.1. Body measurements of obese mice with AuNP treatment.....	208
5.3.2.2. mRNA expression of inflammatory and adipokine markers in the adipose tissue .....	210
5.3.2.3. mRNA expression of inflammatory, lipid, and glucose markers in the liver .....	211
5.3.2.4. Distribution of gold in the organs .....	212
5.4. Discussion .....	213
6. FUTURE STUDIES AND CONCLUSIONS .....	220

7. REFERENCES: .....	225
----------------------	-----

## List of Figures

Figure 1.1 UV-VIS absorption spectra showing SPR bands and peaks for various sizes and shapes of AuNPs. Adapted from (Eustis & El-Sayed 2006).....	8
Figure 1.2 Transmission electron microscopy (TEM) images and colour intensity of various size and shaped colloidal gold.....	9
Figure 2.1 Preparation of HAuCl <sub>4</sub> stock solution .....	34
Figure 2.2 The Turkevich/Fren citrate sol method for preparation of spherical AuNPs	36
Figure 2.3 Schematic showing direct physisorption of BSA and antibodies, forming protein corona onto AuNP surfaces. ....	37
Figure 2.4 Schematic of MPCs prepared by mixed hetero-functionalized short-chain PEG or long-chain PEG .....	39
Figure 2.5 Representative HR-SEM images of AuNPs before and after PEGylation ....	50
Figure 2.6 Optimization of short-chain PEG per nanoparticle ratio for MPC1, MPC5, and MPC6 .....	53
Figure 2.7 Optimization of long-chain PEG per nanoparticle ratio for MPC3, MPC7, and MPC8 .....	54
Figure 2.8 Shifting of SPR peak with biomolecule-conjugated AuNPs with/without PEGylation .....	56
Figure 2.9 Migration of biomolecules and PEG-modified AuNPs determined using 1% agarose gel electrophoresis .....	61
Figure 2.10 HR-SEM images of BAEC after 24 h treatment with various AuNPs .....	63
Figure 2.11 HR-SEM and EBSD analysis of BAEC treated with anti-CD31-MPC5 for 24 h.....	64
Figure 2.12 Immunofluorescence staining of HCAEC surface antigen CD31 .....	65
Figure 2.13 Preliminary cytotoxic effect of AuNP treatment on BAEC .....	67

Figure 3.1 Visual images capture differentiation of 3T3-L1 pre-adipocytes into mature adipocytes. Images taken under 10 x magnification. ....	79
Figure 3.2 Standard curve of the MTT assay derived from titration of RAW 264.7 macrophages of known concentrations measured at 570 nm. $Y = 0.0632X + 0.2142$ . ..	81
Figure 3.3 Standard curve derived from serial dilution of BSA of known concentration measured at Abs 750 nm, assayed using DC Protein Assay Kit II. $Y = 0.1197 * X + 0.01584$ . ....	82
Figure 3.4 Standard curve derived from NEFA standards measured at 550 nm. $Y = 0.0299X - 0.0002$ . ....	89
Figure 3.5 Standard curve derived glycerol standards measured at 490 nm. $Y = 0.1224X - 0.00348$ . ....	90
Figure 3.6 Effect of AuNP treatment on cell viability and cell number in RAW 264.7 macrophages. ....	95
Figure 3.7 Effect of AuNP treatment on ROS production in RAW 264.7 macrophages .....	96
Figure 3.8 Effect of AuNPs treatment on TLR-4 and TNF- $\alpha$ protein expression in RAW 264.7 macrophages. ....	98
Figure 3.9 Effect of AuNPs treatment on IKK $\alpha$ and IKK $\beta$ protein expression in RAW 264.7 macrophages. ....	99
Figure 3.10 Effects of AuNP treatment on pro-inflammatory markers in RAW 264.7 macrophages. ....	101
Figure 3.11 Effect of AuNP treatment on the cytokine production in PMA-differentiated U937 macrophage-like cells. ....	107
Figure 3.12 Effect of AuNP on the cytokine production in LPS-stimulated PMA-differentiated U937 macrophage-like cells .....	110
Figure 3.13 Effect of AuNP treatment on 3T3-L1 adipocyte differentiation .....	114
Figure 3.14 Effect of AuNP treatment on the cell viability of 3T3-L1 adipocytes .....	115



Figure 3.15 Effect of AuNP treatment on ROS production in 3T3-L1 adipocytes.....	115
Figure 3.16 Effect of AuNP treatment on neutral lipids in 3T3-L1 adipocytes.....	119
Figure 3.17 Effect of AuNP treatment on lipid accumulation in 3T3-L1 adipocytes...	120
Figure 3.18 Effect of insulin-mediated glucose uptake in AuNP on 3T3-L1 adipocytes .....	122
Figure 3.19 Effects of AuNP treatment on adipokine markers in 3T3-L1 adipocytes .	123
Figure 3.20 Effects of AuNP treatment on the cell viability of co-cultured adipocytes- macrophages.....	125
Figure 3.21 Effect of AuNP treatment on ROS production for adipocyte-macrophage co-cultures .....	125
Figure 3.22 Effect of AuNP treatment on adipokine and pro-inflammatory markers in co-cultured adipocyte-macrophage .....	129
Figure 4.1 Standard curve derived from titration of insulin using mouse insulin Enzyme- Linked Immunosorbent Assay kit. $Y = 0.3219X + 0.04768$ .....	144
Figure 4.2 Standard curve derived from titration cholesterol using Cholesterol Fluorometric assay kit. $Y = 85.71 * X + 6.290$ .....	145
Figure 4.3 Effects of 9 weeks HFD and AuNP treatment on energy consumption and body weight of C57Bl/6 mice. ....	155
Figure 4.4 Effects of 9 weeks HFD and AuNP treatment on glucose tolerance.....	156
Figure 4.5 Effects of 9 weeks HFD and AuNP treatment on the adipose size in mesenteric adipose tissue determined by H&E staining .....	159
Figure 4.6 Effects of 9 weeks HFD and AuNP treatment on macrophage and inflammatory markers in abdominal fat.....	162
Figure 4.7 Effects of 9 weeks HFD and AuNP treatment on lipid and glucose metabolic markers in abdominal fat.....	164
Figure 4.8 Effects of 9 weeks HFD and AuNP treatment on macrophage and inflammatory markers in the liver.....	167

Figure 4.9 Effects of 9 weeks HFD and AuNP treatment on lipid and glucose metabolic markers in the liver.....	169
Figure 5.1 Standard curve derived from cholesterol standards ( $Y = 0.1772X + 0.4135$ ). .....	187
Figure 5.2 Effects of 15 weeks HFD with 5 weeks AuNP treatment on food intake and body weight in male mice. ....	192
Figure 5.3 Effect of 15 weeks HFD with 5 weeks AuNP treatment on glucose tolerance .....	193
Figure 5.4 Effects of 15 weeks HFD with 5 weeks AuNP treatment on adipose size in the epididymal adipose tissue determined by H&E and F4/80 staining for CLS .....	197
Figure 5.5 Effect of 15 weeks HFD with 5 weeks AuNP treatment on macrophage and inflammatory markers in retroperitoneal fat .....	200
Figure 5.6 Effect of 15 weeks HFD with 5 weeks AuNP treatment on lipid and glucose metabolic markers in retroperitoneal fat .....	202
Figure 5.7 Effect of 15 weeks HFD with 5 weeks AuNP treatment on macrophage and inflammatory markers in the liver.....	205
Figure 5.8 Effect of 15 weeks HFD with 5 weeks AuNP treatment on lipid and glucose metabolic markers in the liver.....	207

## List of Tables

Table 1.1 A summary of <i>in vivo</i> toxicity and biocompatibility studies using unmodified or modified AuNPs. Modified from (Zhang et al. 2010).	13
Table 1.2 International BMI classification of underweight, overweight, and obesity for adults. Adapted from (NHLBI 1998; WHO 2015a).	15
Table 1.3 Waist circumferences and waist-hip ratio for adults predicts risk of metabolic complications. Adapted from (WHO 2008).	16
Table 1.4 Pharmacotherapy used in obesity management in Australia. Adapted from (Lee & Dixon 2017).	25
Table 2.1 List of summary for biomolecule and/or PEGylated AuNPs prepared and studied in this chapter.	41
Table 2.2 Particle size and hydrodynamic diameter using HR-SEM and DLS	51
Table 2.3 Quantification of colloidal gold concentration before and after PEGylation using ICP-MS.	57
Table 2.4 Critical flocculation concentration of AuNPs before and after PEGylation	58
Table 2.5 Surface $\zeta$ potential measured using Malvern NanoZS	59
Table 3.1 Details of materials used for macrophage and adipocyte cultures	75
Table 3.2 Reagent composition for TaqMan® gene expression assay	85
Table 3.3 RT-PCR amplification program for TaqMan® gene expression assay	86
Table 3.4 Taqman® gene expression assay primer sequences	87
Table 3.5 Effect of AuNP treatment on the 3T3-L1 adipocytes (> 800 cells)	119
Table 3.6 Effect of AuNP treatment on lipid metabolism in 3T3-L1 adipocytes.	120
Table 4.1 Summary of animal feed composition according to manufacturer.	141
Table 4.2 TaqMan® gene expression assay primer sequences	150
Table 4.3 SYBR® Green gene expression assay primer sequences	150

Table 4.4 Reagent composition for SYBR® Green gene expression assay .....	151
Table 4.5 RT-PCR amplification program for SYBR® Green gene expression assay	151
Table 4.6 Effect of 9 weeks HFD and AuNP treatment on body morphometry .....	157
Table 4.7 Effect of 9 weeks HFD and AuNP treatment on mice body metabolic parameters in non-fasting state.....	158
Table 4.8 Concentration of gold measured in the organs after 9 weeks of AuNPs treatment.....	174
Table 5.1 Effect of 15 weeks of HFD with 5 weeks of AuNP treatment on body morphometry .....	194
Table 5.2 Effect of 15 weeks of HFD with 5 weeks of AuNP treatment on mice body metabolic parameters in non-fasting state.....	195
Table 5.3 Concentration of Au in the organs after 5 weeks of AuNPs treatment.....	212

## Abbreviations

AC	adipocytes control
AF594	Alexa Fluor 594 cadevarine
AF594	Alexa Fluor 594 cadaverine
AH	adipocytes treated with high dose of AuNPs
AHH	adipocytes treated with extremely high dose of AuNPs
AL	adipocytes treated with low dose of AuNPs
ALT	alanine aminotransferase
ANOVA	analysis of variance
ARMΦC	adipocyte-macrophage co-culture control
ARMΦH	adipocyte-macrophage co-culture treated with high dose of AuNPs
ARMΦHH	adipocyte-macrophage co-culture treated with extremely high dose of AuNPs
ARMΦL	adipocyte-macrophage co-culture treated with low dose of AuNPs
AST	aspartate aminotransaminase
ATGL	adipose triglyceride lipase
ATM	adipose tissue macrophage
AUC	area under the curve
AuCl <sub>4</sub>	chloroaurate
AuNP	gold nanoparticle
BAEC	bovine aortic endothelial
BMI	body mass index
BSA	bovine serum albumin

BSA-AuNP	BSA-conjugated AuNPs
CD	cluster of differentiation
cDNA	complementary DNA
Chow-C	chow-fed mice control
CLS	crown-like structure
CPT	carnitine palmitoyl transferase
DCF	2',7'-dichlorofluorescein
DEPC	diethylpyrocarbonate
DL	detection limit
DMEM	dulbecco's modified eagle's medium
DNA	deoxyribonucleic acid
DNase	deoxyribonuclease
dNTP	deoxyucleotide
DPBS	dulbecco's PBS
EDTA	ethylenediaminetetraacetic acid
EDC	1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
F4/80	expressing ATMs
FASN	fatty acid synthase
FBS	fetal bovine serum
FOX	forkhead box
GLUT	glucose transporter
GM-CSF	granulocyte-macrophage colony-stimulating factor
H&E	harris haematoxylin and eosin

H <sub>2</sub> -DCFDA	2',7'-dichlorofluorescein diacetate
HAuCl <sub>4</sub>	tetrachloroauric acid
HCAEC	human coronary artery endothelial cell
HFD	high fat diet
HFD-C	HFD-fed mice control
HFD-HAu	HFD-fed mice treated with high doses AuNPs
HFD-LAu	HFD-fed mice treated with low dose of AuNPs
HRP	horseradish peroxidase
HR-SEM	high resolution scanning electron microscopy
ICP-MS	inductively-coupled plasma mass spectroscopy
IFN	interferon
IKK	inhibitory kappa kinase
IL	interleukin
IP	intraperitoneal
IPGTT	intraperitoneal glucose tolerance test
IκB	inhibitory kappaB
LPS	lipopolysaccharide
M1	pro-inflammatory macrophage
M2	anti-inflammatory macrophage
MES	2-( <i>N</i> -morpholino)ethanesulfonic acid
MΦ	macrophage
MPC	monolayer protected cluster
mRNA	messenger RNA

MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NCS	new calf serum
NEFA	non-esterified fatty acid
NF- $\kappa$ B	nuclear factor-kappa B
NHS	N-hydroxysuccinimide
OB-C	obese mice control
OB-EAu	obese mice treated with extremely low dose of AuNPs
OB-HAu	obese mice treated with high dose of AuNPs
OB-LAu	obese mice treated with low dose of AuNPs
P/S	penicillin and streptomycin
PBS	phosphate buffered saline
PC	pre-adipocyte or 3T3-L1 fibroblast control
PCR	polymerase chain reaction
PEG	polyethelyne glycol
PEPCK	phosphoenolpyruvate carboxykinase
pf-DMEM	phenol-red free Dulbecco's Modified Eagle Medium
PMA	phorbol 12-myristate 13-acetate
PPAR	peroxisome proliferator-activated receptor
RM $\Phi$	RAW 264.7 macrophages
RM $\Phi$ C	RAW 264.7 macrophages control
RM $\Phi$ H	RAW 264.7 macrophages treated with high dose of AuNPs
RM $\Phi$ HH	RAW 264.7 macrophages treated with extremely high dose of AuNPs



RMΦL	RAW 264.7 macrophages treated with low dose of AuNPs
RMΦLPSH	high dose LPS stimulated RAW 264.7 macrophage
RMΦLPSL	low dose LPS stimulated RAW 264.7 macrophages
RNA	ribonucleic acid
ROS	reaction oxygen speacies
RPMI	roswell park memorial institute
RT-PCR	real-time PCR
S.E.M	standard mean of error
SAA	serum amyloid A
SPR	surface plasmon resonance
SREBP	sterol regulatory element binding protein
TEM	transmission electron microscopy
TLR-4	toll-like receptor-4
TNF	tumor necrosis factor
UMΦ	U937 monocytes
UMΦC	PMA-differentiated U937 control
UMΦC_LPS	PMA-differentiated U937 with LPS stimulation control
UMΦH	PMA-differentiated U937 treated with high dose AuNP
UMΦH_LPS	PMA-differentiated U937 treated with high dose AuNPs and LPS
UMΦ_HH	PMA-differentiated U937 treated-with extremely high dose AuNPs
UMΦ_HH_LPS	PMA-differentiated U937 treated with extremely high dose AuNPs and LPS
UMΦL	PMA-differentiated U937 treated with low dose AuNPs